Cargando…

Cross-talk between p21-activated kinase 4 and ERα signaling triggers endometrial cancer cell proliferation

Cross-talk between estrogen receptor alpha (ERα) and signal transduction pathways plays an important role in the progression of endometrial cancer (EC). Here, we show that 17β-estradiol (E(2)) stimulation increases p21-activated kinase 4 (Pak4) expression and activation in ER-positive EC cells. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Tao, Qu, Jun-Jie, Wang, Kai, Li, Bi-Lan, Zhao, Dong, Zhu, Yi-Ping, Ye, Lei, Lu, Wen, Wan, Xiao-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620238/
https://www.ncbi.nlm.nih.gov/pubmed/28978098
http://dx.doi.org/10.18632/oncotarget.19188
Descripción
Sumario:Cross-talk between estrogen receptor alpha (ERα) and signal transduction pathways plays an important role in the progression of endometrial cancer (EC). Here, we show that 17β-estradiol (E(2)) stimulation increases p21-activated kinase 4 (Pak4) expression and activation in ER-positive EC cells. The estrogen-induced Pak4 activation is mediated via the PI3K/AKT pathway. Estrogen increases Pak4 and phosphorylated-Pak4 (p-Pak4) nuclear accumulation, and Pak4 in turn enhances ERα trans-activation. Depletion or functional inhibition of Pak4 abrogates EC cell proliferation induced by E(2), whereas overexpression of Pak4 rescues cell proliferation decreased by inhibiting the estrogen pathway. Pak4 knockdown decreases cyclin D1 expression and induces G1-S arrest. Importantly, Pak4 suppression inhibits E(2) induced EC tumor growth in vivo, in a mouse xenograft model. These data demonstrate that estrogen stimulation increases Pak4 expression and activation, which in turn enhances ERα transcriptional activity and ERα-dependent gene expression, resulting in increased proliferation of EC cells. Thus inhibition of Pak4-ERα signaling may represent a novel therapeutic strategy against endometrial carcinoma.